Navigation Links
FDA Accords Priority Review For Pediatric Crohn's Disease Drug

The U.S. Food and Drug Administration (FDA) has decided to accord a priority review for the drug REMICADE (R) (infliximab) to be used in the treatment of pediatric// Crohn's disease, the drug's manufacturer Centocor, Inc. announced today. Crohn's disease affects the gastrointestinal tract and causes diarrhea, fever, abdominal pain and weight loss. As of now there is no drug to treat children who develop this condition. Centocor had filed a supplemental Biologics License Application (sBLA), which was accepted by the FDA.

The filing is based primarily on Phase 3 study results showing the unprecedented efficacy of REMICADE in the treatment of children with moderately to severely active Crohn's disease. In the REACH (a Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF Monoclonal Antibody REMICADE in Pediatric Subjects with Moderate to Severe Crohn's Disease) trial, nearly 90 percent (88.4 percent) of pediatric patients with moderately to severely active Crohn's disease who had an inadequate response to conventional therapy achieved clinical response at week 10 when treated with REMICADE. Nearly two-thirds (63.5 percent) of the patients who were randomized to treatment with REMICADE every 8 weeks were in clinical response at one year. Additionally, more than half of the patients treated with REMICADE every 8 weeks were in clinical remission at the end of one year.

"We are extremely pleased by the results of the REACH trial and by the FDA's decision to accept the application with a Priority Review," said Jerome A. Boscia, MD, Senior Vice President, Clinical Research and Development, Centocor, Inc. "REMICADE, if approved for the treatment of pediatric Crohn's disease, would represent a major advancement for children with this serious condition. We look forward to working closely with the FDA as it reviews these data for approval."

Priority Review is granted by the FDA to products that are considered to be a potential therapeutic advance over current therapies. Acceptance of the sBLA filing does not mean that a license has been issued for this indication nor does it represent any evaluation of the adequacy of the data submitted in the sBLA. REMICADE was FDA-approved in 1998 as the first biologic treatment for adults with moderate to severe Crohn's disease. In September 2005, REMICADE also became the first approved biologic treatment for moderate to severe ulcerative colitis (UC), making it the only biologic indicated for the treatment of both types of inflammatory bowel disease (IBD) in adults. Contact: Michael Parks 215-983-8000 Centocor, Inc. Source: Eurekalert
'"/>




Related medicine news :

1. British MPs Say Prostate Cancer Receives Low Priority in the NHS
2. Funds Pumped In To Reduce Waiting List of Priority Patients
3. Children Health Care To Be Given Priority
4. Hypertension Not Given Priority during Treatment
5. Healthcare And Education Top Most Priority Of The Govt: Nitish
6. Global Health Issues To Take Priority In The Current G8 Summit In Russia
7. Consistent National Standards For Assessment Of Overseas Trained Doctors A Priority
8. Women and Children Issues Should Get Priority in India
9. WHO Urges Higher Priority for Neglected Diseases
10. COAG Must Make Combating Severe Allergies A National Priority
11. Priority Needs to Be Given to Maternal Health in Afghanistan
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/16/2018)... ... 16, 2018 , ... The months of training are over. The race has come and gone. ... like they were put through the wringer after the big event. Read on for something ... in Motion on how to treat the body and mind after a long run: , ...
(Date:10/13/2018)... PHOENIX (PRWEB) , ... October 12, 2018 , ... At ... pleased to announce they will be attending this year’s National Healthcare CXO Fall Summit ... event to discuss key Patient Access and Patient Experience challenges with leading healthcare providers. ...
(Date:10/13/2018)... , ... October 13, 2018 , ... This World Food ... world that it IS possible to end hunger by 2030 by breaking a GUINNESS ... from several of their 28 U.S. based locations and five international locations together to ...
(Date:10/11/2018)... (PRWEB) , ... October 11, 2018 , ... ... for 2018. The medalists are leading scientists in their fields recognized by DuPont ... advancing science and technology relevant to the future of food, nutrition and health. ...
(Date:10/11/2018)... ... 2018 , ... Bizmatics Inc. is a healthcare technology company ... PrognoCIS , their Health IT Software – provides physicians with tools that promote ... the region’s health information exchange (HIE), serves 24 counties in South East Texas. ...
Breaking Medicine News(10 mins):
(Date:10/5/2018)... SPRINGS, Fla. (PRWEB) , ... October 05, 2018 ... ... the nation’s leading innovative specialty pharmacies, announces the donation of $12,000 from a ... and South Carolina by Hurricane Florence. BioPlus serves as a partner for specialty ...
(Date:10/5/2018)... ANGELES (PRWEB) , ... October 05, 2018 , ... A September 20th article ... falling from a rented scooter. The death was ruled to be the result of a ... increasing scooter injuries nationwide and a new California law legalizing helmetless scooter driving for adults. ...
(Date:10/5/2018)... ... 2018 , ... The International Association of Eating Disorder Professionals ... Me Beyond What You See” Body Image Mannequin Art Competition, created in 2010 ... mannequins to help create a unique and realistic palette for artistic expression. ...
Breaking Medicine Technology: